TRKC (G696A)
Sign in to save this workspaceNTRK3 · Variant type: point · HGVS: p.G696A
Drug response on this variant
| # | Drug | Inhibition on variant | Residual | KISS |
|---|---|---|---|---|
| 1 | Cabozantinib | 99.5% | 0.5% | 92.73 |
| 2 | Entrectinib | 99.4% | 0.6% | 93.69 |
| 3 | Repotrectinib | 99.0% | 1.0% | 84.21 |
| 4 | Pralsetinib | 98.8% | 1.1% | 93.43 |
| 5 | Alpelisib | 98.3% | 1.7% | 97.22 |
| 6 | Quizartinib | 95.4% | 4.6% | 99.50 |
| 7 | Ripretinib | 93.8% | 6.2% | 92.95 |
| 8 | Tivozanib | 93.3% | 6.7% | 92.42 |
| 9 | Pacritinib | 92.9% | 7.1% | 88.64 |
| 10 | Gilteritinib | 92.2% | 7.8% | 88.97 |
| 11 | Regorafenib | 91.7% | 8.3% | 95.99 |
| 12 | Sunitinib | 91.1% | 8.9% | 91.73 |
| 13 | Tenalisib | 90.6% | 9.4% | 97.98 |
| 14 | Sorafenib | 88.4% | 11.6% | 96.72 |
| 15 | Defactinib | 74.5% | 25.6% | 92.68 |
| 16 | Darovasertib | 62.5% | 37.5% | 96.99 |
| 17 | Alectinib | 58.6% | 41.4% | 95.49 |
| 18 | Rabusertib | 52.2% | 47.8% | 98.74 |
| 19 | Fostamatinib | 43.0% | 57.0% | 96.74 |
| 20 | Futibatinib | 42.6% | 57.4% | 98.48 |
| 21 | Selpercatinib | 36.9% | 63.1% | 96.72 |
| 22 | Abemaciclib | 34.1% | 65.9% | 91.48 |
| 23 | Lorlatinib | 33.2% | 66.8% | 97.24 |
| 24 | Fedratinib | 31.7% | 68.3% | 96.21 |
| 25 | Upadacitinib | 31.5% | 68.5% | 97.98 |
Wild-type vs variant — drug response delta
Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).
| Drug | Variant inh | WT inh | Δ (variant − WT) |
|---|---|---|---|
| Cabozantinib | 99.5% | — | — |
| Entrectinib | 99.4% | 98.8% | +0.6% |
| Repotrectinib | 99.0% | 98.9% | +0.2% |
| Pralsetinib | 98.8% | 99.4% | -0.6% |
| Alpelisib | 98.3% | 99.3% | -0.9% |
| Quizartinib | 95.4% | — | — |
| Ripretinib | 93.8% | — | — |
| Tivozanib | 93.3% | 96.1% | -2.8% |
| Pacritinib | 92.9% | 96.7% | -3.8% |
| Gilteritinib | 92.2% | 99.0% | -6.8% |
| Regorafenib | 91.7% | — | — |
| Sunitinib | 91.1% | 95.4% | -4.2% |
| Tenalisib | 90.6% | 98.1% | -7.5% |
| Sorafenib | 88.4% | — | — |
| Defactinib | 74.5% | 91.7% | -17.2% |
| Darovasertib | 62.5% | 94.5% | -32.0% |
| Alectinib | 58.6% | 94.2% | -35.6% |
| Rabusertib | 52.2% | — | — |
| Fostamatinib | 43.0% | — | — |
| Futibatinib | 42.6% | — | — |
| Selpercatinib | 36.9% | — | — |
| Abemaciclib | 34.1% | — | — |
| Lorlatinib | 33.2% | 91.3% | -58.2% |
| Fedratinib | 31.7% | — | — |
| Upadacitinib | 31.5% | — | — |
Annotations
Sign in to read and post annotations.
Loading…
Served from saifudeen2026@1.0.0 · API 0.1.0 · 14.3ms